Stockscreener 앱 받기
93.23
0.96%
-0.90
시간 외 거래:
94.35
1.12
+1.20%
전일 마감가:
$94.13
열려 있는:
$93.81
하루 거래량:
4.28M
Relative Volume:
0.63
시가총액:
$119.58B
수익:
$34.20B
순이익/손실:
$4.69B
주가수익비율:
25.74
EPS:
3.6218
순현금흐름:
$5.30B
1주 성능:
-2.71%
1개월 성능:
-1.05%
6개월 성능:
+10.94%
1년 성능:
+2.90%
1일 변동 폭
$93.21
$94.59
1주일 범위
$91.87
$97.24
52주 변동 폭
$79.29
$99.37
메드트로닉 Stock (MDT) Company Profile
명칭
Medtronic Plc
전화
01135314381700
주소
BUILDING TWO PARKMORE BUSINESS PARK WEST, GALWAY
MDT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MDT
Medtronic Plc
|
93.23 | 120.73B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
ABT
Abbott Laboratories
|
126.61 | 221.35B | 43.84B | 13.94B | 6.78B | 7.9979 |
|
BSX
Boston Scientific Corp
|
100.97 | 151.78B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
375.93 | 146.70B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
EW
Edwards Lifesciences Corp
|
82.19 | 47.45B | 5.69B | 1.41B | 577.90M | 6.9828 |
메드트로닉 Stock (MDT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-30 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2025-06-16 | 개시 | Leerink Partners | Outperform |
| 2025-03-04 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-10-10 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-08-21 | 재확인 | Oppenheimer | Perform |
| 2024-08-15 | 업그레이드 | UBS | Sell → Neutral |
| 2024-08-14 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Sell |
| 2023-07-19 | 개시 | Robert W. Baird | Neutral |
| 2023-06-30 | 개시 | CL King | Buy |
| 2023-05-30 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-04-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-29 | 다운그레이드 | UBS | Buy → Sell |
| 2023-01-09 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-11-23 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-11-23 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-11-16 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2022-10-18 | 개시 | Barclays | Equal Weight |
| 2022-10-13 | 개시 | Mizuho | Buy |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-08-24 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-06-01 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2022-05-27 | 다운그레이드 | Needham | Buy → Hold |
| 2022-04-13 | 다운그레이드 | Truist | Buy → Hold |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-10 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-01-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-12-17 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-12-16 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-06-10 | 재개 | Cowen | Outperform |
| 2021-05-25 | 개시 | Barclays | Equal Weight |
| 2021-04-15 | 개시 | Atlantic Equities | Overweight |
| 2020-12-15 | 업그레이드 | Goldman | Sell → Neutral |
| 2020-12-15 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-10-08 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2020-10-08 | 업그레이드 | Stifel | Hold → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Peer Perform |
| 2020-05-14 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2020-03-30 | 다운그레이드 | Needham | Strong Buy → Buy |
| 2020-03-25 | 업그레이드 | DZ Bank | Hold → Buy |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Sell |
| 2020-01-08 | 개시 | SunTrust | Buy |
| 2020-01-02 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-06-05 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2019-02-04 | 재확인 | Needham | Strong Buy |
| 2019-01-03 | 개시 | Deutsche Bank | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2018-12-19 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-11-28 | 개시 | UBS | Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-08-27 | 재확인 | Argus | Buy |
모두보기
메드트로닉 주식(MDT)의 최신 뉴스
CMS finalizes renal denervation coverage that benefits Medtronic, Recor - MassDevice
Medtronic (MDT) Gains CMS Approval for Innovative Blood Pressure Treatment - GuruFocus
U.S. Centers for Medicare & Medicaid Services finalizes National Coverage Determination for the Medtronic Symplicity Spyral™ renal denervation (RDN) system - The Malaysian Reserve
Medtronic (NYSE: MDT) receives CMS NCD coverage for Symplicity Spyral renal denervation - Stock Titan
Will Medtronic’s RDN study drive Spyral-ing growth? - BioWorld MedTech
Medtronic links renal denervation to 3-year blood pressure reduction - MedTech Dive
What high frequency data says about Medtronic plcWeekly Volume Report & Target Return Focused Picks - newser.com
What downside risks could hit Medtronic plc (2M6) stockBond Market & Weekly Chart Analysis and Trade Guides - newser.com
Detecting support and resistance levels for Medtronic plcInsider Buying & Fast Gain Stock Trading Tips - newser.com
Is Medtronic plc (2M6) stock cheap by valuation metrics2025 Trade Ideas & Smart Swing Trading Techniques - newser.com
Is Medtronic plc (2M6) stock expanding market penetrationEarnings Risk Report & Free Real-Time Volume Trigger Notifications - newser.com
Will Medtronic plc. Ordinary Shares stock outperform value peersJuly 2025 PreEarnings & Long-Term Capital Growth Strategies - newser.com
Is Medtronic plc (2M6) stock nearing a technical breakoutJuly 2025 Catalysts & Entry and Exit Point Strategies - newser.com
Why Medtronic plc. Ordinary Shares stock could be next leader2025 Geopolitical Influence & Accurate Intraday Trading Signals - Fundação Cultural do Pará
How to interpret RSI for Medtronic plc stockLayoff News & Growth Focused Stock Reports - newser.com
How Medtronic plc (2M6) stock behaves under inflation pressure2025 Bull vs Bear & Weekly Momentum Stock Picks - Fundação Cultural do Pará
Medtronic shares first results from new Symplicity Spyral RDN study - MassDevice
Will Medtronic plc. Ordinary Shares stock hit Wall Street targetsJuly 2025 Technicals & Expert-Curated Trade Recommendations - Fundação Cultural do Pará
Medtronic : Impact Report Assurance Statement (impact report assurance statement) - MarketScreener
Medtronic : Stakeholder Engagement Disclosure (stakeholder engagement disclosure) - MarketScreener
Medtronic gains millions in tax incentives for Massachusetts expansion - MassDevice
What to Expect From Medtronic's Q2 2026 Earnings Report - MSN
Is Medtronic plc stock attractive for growth ETFs2025 Top Gainers & Short-Term Trading Opportunity Alerts - Fundação Cultural do Pará
Is Medtronic plc stock ready for a breakout2025 Short Interest & Real-Time Volume Triggers - newser.com
Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial - GlobeNewswire Inc.
Will Medtronic plc stock return to pre crisis levelsJuly 2025 Short Interest & AI Powered Buy/Sell Recommendations - newser.com
Medtronic plc stock trend forecastQuarterly Risk Review & Free Expert Verified Stock Movement Alerts - newser.com
Medtronic reports 3-year blood pressure reductions with Symplicity Spyral RDN - MassDevice
Medtronic (MDT) Reveals Promising Long-Term Blood Pressure Reduc - GuruFocus
Medtronic plc Announces New, Long-Term Results from Its Final Report of the SPYRAL HTN-ON Med Randomized Clinical Trial - MarketScreener
Medtronic (MDT) Prepares for US Launch of HUGO Surgical Robot, Says Stifel - MSN
Medtronic: A Revitalized Dividend Aristocrat To Buy Now (NYSE:MDT) - Seeking Alpha
메드트로닉 (MDT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.03%
1.70%
자본화:
|
볼륨(24시간):